Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$16.6MCash on Hand
56.8mo Cash Runway
Follow TKNO by emailGet an email when TKNO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TKNO, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 4, 2026 ·
Earnings Q3 2026 revenue was $12.7 million, up 22% from $10.5 million a year earlier, and the company raised 2026 revenue guidance to $46-48 million. It closed a 9,200,000-share offering at $5.00 per share for gross proceeds of $46.0 million on October 22, 2026. Form 8-K · SEC filing · Press release
Oct 21, 2026 ·
Financing Alpha Teknova is offering 8,000,000 shares of common stock at $5.0000 per share, for proceeds before expenses of $37,600,000. The underwriters have a 30-day option to buy up to 1,200,000 more shares. The stock closed at $6.80 on October 19, 2026. Form 424B5 · SEC filing
Oct 21, 2026 ·
Financing Teknova priced an underwritten offering of 8,000,000 shares at $5.00 per share, with an option for 1,200,000 more, for gross proceeds of $40 million before costs. Preliminary Q3 revenue was $12.5 million to $12.7 million, with $16.6 million in cash. Form 8-K · SEC filing · Press release
Oct 20, 2026 ·
Financing Alpha Teknova proposes a public offering of common stock, with the share count, price and underwriter discount left blank in this preliminary prospectus. The offering is made under a shelf registration of up to $225,000,000 in total, and the underwriters have a 30-day option on additional shares. Form 424B5 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · N/A · Recruiting · Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients Registry primary completion date, not a results date
Dec 2026 · N/A · Recruiting · Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC Registry primary completion date, not a results date
Dec 2026 · N/A · Active Trial · Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT) Registry primary completion date, not a results date
Jan 2027 · N/A · Recruiting · Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer Registry primary completion date, not a results date
Jan 2027 · N/A · Recruiting · Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia Registry primary completion date, not a results date
Jan 2027 · N/A · Recruiting · Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not TKNO's own candidates): Pembrolizumab, Erlotinib Hydrochloride, Gefitinib, Trifluridine And Tipiracil, Carboplatin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
TKNO holds $16.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $874,500/quarter from operations,
an estimated runway of 56.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:7 · Low
Cash runway 57 months
Shelf registration (S-3, Jul 2025) +10
Share count +18% in a year +7
Raised after last reported balance sheet (Oct 2026) -10
Recent financing filings on SEC EDGAR:
Oct 21, 2026 · Underwritten offering, $40M · 424B5
Share count 62,903,130 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full TKNO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TKNO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.